Dashboard
Manage Tickers

INKT MiNK Therapeutics, Inc.

Nasdaq minktherapeutics.com


$ 13.00 $ -0.43 (-3.15 %)    

Friday, 07-Nov-2025 16:53:02 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 13.23
$ 13.65
$ 12.63 x 10
$ 14.01 x 170
$ 13.13 - $ 13.75
$ 4.56 - $ 76.00
26,429
na
59.84M
$ 2.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-18-2022 12-31-2021 10-K
16 11-29-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

mink-therapeutics-files-for-mixed-shelf-offering-up-to-150m
MiNK Therapeutics Files For Mixed Shelf Of...
11/07/2025 22:01:04

-SEC Filing

mink-therapeutics-presents-updated-clinical-results-evaluating-agent-797-alone-and-in-combination-with-anti-pd-1-therapy-in-patients-with-advanced-solid-tumors-refractory-to-all-approved-treatments-at-sitc-2025
MiNK Therapeutics Presents Updated Clinica...
11/07/2025 14:07:38

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months...

mink-therapeutics-announces-that-late-breaking-phase-1-data-for-its-allogeneic-inkt-cell-therapy-agent-797-will-be-presented-at-40th-annual-sitc-meeting-nov-79-2025
MiNK Therapeutics Announces That Late-Brea...
10/30/2025 13:03:23

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural kille...

hc-wainwright--co-upgrades-mink-therapeutics-to-buy-maintains-price-target-to-35
HC Wainwright & Co. Upgrades MiNK Therapeu...
08/15/2025 11:03:17

HC Wainwright & Co. analyst Emily Bodnar upgrades MiNK Therapeutics (NASDAQ:INKT) from Neutral to Buy and maintains the ...

mink-therapeutics-q2-eps-106-misses-046-estimate
MiNK Therapeutics Q2 EPS $(1.06) Misses $(...
08/14/2025 11:33:45

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/15/2025 17:06:53

hc-wainwright--co-downgrades-mink-therapeutics-to-neutral-maintains-price-target-to-35
HC Wainwright & Co. Downgrades MiNK Therap...
07/15/2025 15:04:22

HC Wainwright & Co. analyst Emily Bodnar downgrades MiNK Therapeutics (NASDAQ:INKT) from Buy to Neutral and maintains th...

simulations-plus-fb-financial-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Simulations Plus, FB Financial And Other B...
07/15/2025 12:40:03

mink-therapeutics-highlights-inkt-cell-therapy-potential-in-peer-reviewed-article-titled-car-inkt-cells-redefining-the-frontiers-of-cellular-immunotherapy-underscoring-the-power-of-car-inkt-as-next-gen-solid-tumor-treatment
MiNK Therapeutics Highlights iNKT Cell The...
07/15/2025 12:25:00

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural kille...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/15/2025 12:07:58

why-trade-desk-shares-are-trading-higher-by-15-here-are-20-stocks-moving-premarket
Why Trade Desk Shares Are Trading Higher B...
07/15/2025 11:24:36

william-blair-downgrades-mink-therapeutics-to-market-perform
William Blair Downgrades MiNK Therapeutics...
07/14/2025 18:17:11

William Blair analyst Matt Phipps downgrades MiNK Therapeutics (NASDAQ:INKT) from Outperform to Market Perform.

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
07/14/2025 17:06:03

ultragenyx-pharmaceutical-apple-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Ultragenyx Pharmaceutical, Apple And Other...
07/14/2025 12:14:56

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
07/14/2025 12:08:12

why-datavault-ai-shares-are-trading-higher-by-7-here-are-20-stocks-moving-premarket
Why Datavault AI Shares Are Trading Higher...
07/14/2025 09:39:47

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
07/11/2025 21:06:01

crude-oil-rises-sharply-milestone-pharmaceuticals-shares-plunge
Crude Oil Rises Sharply; Milestone Pharmac...
07/11/2025 18:37:03

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
07/11/2025 17:06:03

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION